HSBC Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$593K Buy
1,101
+1
+0.1% +$478 ﹤0.01% 2147
2025
Q4
$646K Buy
+1,100
New +$562K ﹤0.01% 2178
2025
Q3
Sell
-1,014
Closed -$309K 2975
2025
Q2
$309K Buy
+1,014
New +$302K ﹤0.01% 2418
2025
Q1
Sell
-2,091
Closed -$643K 3184
2024
Q4
$643K Buy
2,091
+515
+33% +$145K ﹤0.01% 2029
2024
Q3
$338K Buy
1,576
+6
+0.4% +$1.53K ﹤0.01% 2256
2024
Q2
$440K Sell
1,570
-20,787
-93% -$4.95M ﹤0.01% 2045
2024
Q1
$5.95M Buy
22,357
+5,408
+32% +$1.27M ﹤0.01% 1038
2023
Q4
$3.92M Buy
16,949
+2,706
+19% +$474K ﹤0.01% 1241
2023
Q3
$2.08M Hold
14,243
﹤0.01% 1435
2023
Q2
$3.29M Buy
14,243
+3,353
+31% +$908K ﹤0.01% 1232
2023
Q1
$2.64M Buy
+10,890
New +$2.97M ﹤0.01% 1399

Other funds holding MDGL

HSBC Holdings's MDGL Position: Q1 2026 in Review

HSBC Holdings increased its Madrigal Pharmaceuticals (MDGL) stake by 0.09% in Q1 2026, buying an estimated $478 and bringing the position to 1,101 shares worth $593K. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

HSBC Holdings first reported a position in MDGL in Q1 2023 and has held it in 11 quarters since. The position peaked at $5.95M in Q1 2024. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • HSBC Holdings held 1,101 shares of Madrigal Pharmaceuticals worth $593K as of Q1 2026.
  • HSBC Holdings bought 1 Madrigal Pharmaceuticals share in Q1 2026, an estimated $478.
  • Madrigal Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2147 holding.
  • HSBC Holdings first reported a position in Madrigal Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
  • HSBC Holdings's Madrigal Pharmaceuticals position peaked at $5.95M in Q1 2024.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.